Iron, HFE, and overload: what ferritin says and what it does not
Elevated ferritin is one of the most misinterpreted findings in clinical practice. Understanding iron homeostasis, hepcidin, and transferrin saturation separates true overload from a mere inflammatory marker — and distinguishes those who benefit from phlebotomy from those who would simply be bled without indication.
Iron homeostasis and the central role of hepcidin
The body has no physiological pathway for active iron excretion: everything is regulated at the point of entry.
Iron is indispensable — oxygen transport, DNA synthesis, the mitochondrial respiratory chain — and, at the same time, potentially toxic, because free iron catalyzes the formation of radicals that damage tissues. The human body has no regulated mechanism for iron excretion; about 1 to 2 mg is lost per day through cell shedding and physiological bleeding, and the only truly adjustable lever is intestinal absorption. For this reason, the body's iron balance is governed almost entirely at the point of entry and through internal redistribution, not at the exit.
The conductor of this regulation is hepcidin, a peptide hormone produced by the liver. Hepcidin binds to ferroportin — the only known cellular iron exporter, present in enterocytes, macrophages, and hepatocytes — and promotes its internalization and degradation. When hepcidin rises, ferroportin disappears from the membrane: intestinal absorption falls and iron is retained inside macrophages, reducing circulating iron. When hepcidin falls, the opposite occurs: more absorption and more release into the plasma Ganz & Nemeth, 2011.
The stimuli that modulate hepcidin explain much of the clinical picture of iron. Hepcidin rises in iron overload (a protective mechanism) and, above all, in inflammation, via interleukin-6 — hence the anemia of chronic disease, in which iron is present but sequestered. Hepcidin falls in iron deficiency and when erythropoiesis is accelerated, increasing the supply of iron to the marrow. It is precisely in classic hereditary hemochromatosis that this regulation fails: the signaling that should raise hepcidin is impaired, hepcidin remains inappropriately low, and iron is absorbed in excess year after year Ganz & Nemeth, 2011.
Ferritin, in this scenario, is the storage protein: it sequesters iron inside cells in a non-reactive form and, under stable conditions, a fraction is secreted into the plasma in a manner roughly proportional to the stores. This proportionality is the basis for using serum ferritin as an estimate of body stores — and it is also, as we will see, the exact point where clinical interpretation tends to stumble Camaschella, 2015.
Ferritin as an acute-phase reactant: why it alone does not diagnose overload
High ferritin answers many questions at once. In isolation, it answers none of them precisely.
Ferritin is an acute-phase reactant. This means that, in addition to reflecting stores, it rises in response to inflammation, infection, and cell damage — partly through transcriptional induction, partly because ferritin leaks from injured cells into the plasma. Some authors argue that serum ferritin functions, in many contexts, more as a marker of inflammation and tissue injury than as a linear, reliable measure of iron stores Kell & Pretorius, 2014. The practical consequence is direct: an isolated elevated ferritin is not equivalent to iron overload.
The scenarios that raise ferritin without true overload are exactly the most common in the general population. Metabolic syndrome, obesity, insulin resistance, fatty liver disease (steatosis), and high alcohol consumption present with high ferritin as part of a low-grade inflammatory state and hepatic dysfunction — not because the body is accumulating excess iron. The European guidelines are explicit in pointing out that elevated ferritin with normal transferrin saturation points to these non-hemochromatotic causes, and not to hereditary overload Zoller et al., 2022.
Nonalcoholic fatty liver disease illustrates the reasoning trap well. Elevated ferritin in these patients predicts greater histologic severity and a higher probability of advanced fibrosis Kowdley et al., 2012. It is tempting to read this finding as 'iron is causing the damage — so let us remove iron.' But what ferritin is marking here is the underlying inflammation and metabolic dysfunction. This is an association with the outcome, not proof that there is an iron deposit to be bled. Confusing the two is the central conceptual error of this topic.
For this reason, the rule is to interpret ferritin in context, and never in isolation. A landmark review of iron metabolism reinforces that ferritin, being an acute-phase reactant, can be elevated in inflammation without there being either deficiency or true overload Camaschella, 2015. The correct clinical question is not 'is ferritin high?', but 'is ferritin high and is there independent evidence that the iron compartment is in fact increased?'.
| Situation | Real iron overload? | Predominant mechanism of the high ferritin |
|---|---|---|
| Inflammation / acute or chronic infection | No | Acute-phase reactant; IL-6 induction and cellular leakage |
| Metabolic syndrome / insulin resistance | Usually no | Low-grade inflammation and hepatic dysfunction |
| Hepatic steatosis (fatty liver disease) | Usually no | Inflammation and hepatocellular damage; marker of histologic severity |
| High alcohol consumption | Variable | Liver damage and induction of synthesis; true overload is a minority |
| Phenotypic hereditary hemochromatosis (C282Y homozygous with expression) | Yes | Genuinely increased body iron stores |
| Repeated transfusions / secondary overload | Yes | Iron intake that exceeds the capacity for elimination |
Transferrin saturation: the complementary marker and when to investigate overload
Ferritin answers 'how much is in storage'; saturation answers 'how much iron is circulating and available.' The two together change the reading.
If ferritin in isolation is ambiguous, the second essential marker is transferrin saturation — the fraction of circulating transferrin that is actually occupied by iron (serum iron divided by the total binding capacity, as a percentage). While ferritin reflects the store, transferrin saturation reflects iron in transit and tends to rise early when there is true overload, because the influx of iron saturates the transport capacity. It is this complementarity that gives the combination its diagnostic power.
The population evidence that consolidated this pair comes from the HEIRS screening study, which evaluated more than 100,000 adults: transferrin saturation combined with ferritin identifies the overload phenotype far better than ferritin alone, and showed that most carriers of HFE variants do not present clinically relevant overload Adams et al., 2005. In other words, useful screening is not genetic in the first place, but biochemical.
The guidelines converge on this pathway. The AASLD recommends beginning the investigation of overload with transferrin saturation and ferritin, reserving HFE genetic testing for when saturation is elevated Bacon et al., 2011. The American College of Gastroenterology adopts a practical quantitative trigger: transferrin saturation equal to or greater than 45% combined with elevated ferritin justifies investigation and HFE genotyping Kowdley et al., 2019. The corollary, again, is the finding that most guides practice: high ferritin with normal transferrin saturation points to a non-hemochromatotic cause — metabolic, alcoholic, or inflammatory — and not to hereditary overload Zoller et al., 2022.
| Transferrin saturation | Ferritin | Orienting interpretation |
|---|---|---|
| Elevated (≥ 45%) | Elevated | Pattern that most suggests overload — investigate (HFE genotyping, assessment of deposits) |
| Normal | Elevated | Suggests a non-hemochromatotic cause: metabolic syndrome, steatosis, alcohol, inflammation |
| Elevated | Normal | Early phase or variability; reassess serially and within the clinical context |
| Low | Low | Iron deficiency — the opposite scenario; not overload |
| Low | Normal or elevated | Compatible with inflammation / iron sequestration (ferritin as an acute phase) |
Hereditary hemochromatosis, the HFE gene, and incomplete penetrance
Having the variant is not having the disease. Genetics defines population risk; the phenotype defines the patient.
Classic hereditary hemochromatosis, originating in northern Europe, is associated above all with homozygosity for the C282Y variant of the HFE gene, which impairs hepcidin signaling and allows excessive iron absorption over decades. The other HFE genotypic configurations — the H63D variant and simple heterozygosity for C282Y — rarely cause clinically relevant overload on their own, and should not be treated as equivalent to the homozygous disease Powell et al., 2016.
The point most frequently lost in popular discourse is incomplete penetrance. Having the risk genotype does not mean developing the disease. A landmark prospective cohort showed that only about 28% of C282Y homozygous men, and a minority of women, develop disease attributable to iron overload over their lifetime Allen et al., 2008. Most homozygotes, therefore, never become ill from it — and this is a biological characteristic of the genotype, not a failure of follow-up.
Large-scale data confirm and refine this picture. In the UK Biobank, C282Y homozygosity increased the risk of liver disease, diabetes, and arthropathy, but most homozygotes remained without a clinical diagnosis, and heterozygotes and H63D carriers showed much lower risk Pilling et al., 2019. For this reason, the modern definition of hemochromatosis has shifted from the genotype to the phenotype: the disease is the state of demonstrable overload, and not the mere presence of the variant Zoller et al., 2022. A direct-to-consumer genetic test that returns 'you have C282Y' is not, on its own, a diagnosis — it is only the beginning of a phenotype investigation.
| HFE genotype | Risk of clinical overload | Orienting management |
|---|---|---|
| C282Y homozygous | Increased risk, but incomplete penetrance (~28% of men; a minority of women) | Assess the phenotype: transferrin saturation, serial ferritin; treat only if there is documented overload |
| C282Y/H63D (compound heterozygous) | Low; a minority express overload, generally mild | Always interpret with biochemistry; do not presume disease |
| C282Y simple heterozygous | Rarely causes clinical overload in isolation | Does not characterize hemochromatosis on its own |
| H63D (heterozygous or homozygous) | Rarely relevant in isolation | Seek an alternative cause for the high ferritin |
Established overload: organ risk and phlebotomy when truly indicated
Phlebotomy treats documented phenotypic overload. Beyond that, it is bloodletting without a target.
When iron overload is real and untreated, the excess deposits in organs and the clinical risk is substantial. The landmark Lancet Seminar summarizes the spectrum: liver (fibrosis, cirrhosis, and hepatocellular carcinoma), pancreas (diabetes), and heart (cardiomyopathy and arrhythmias), among other manifestations such as arthropathy and endocrine dysfunction Powell et al., 2016. It is this potential for accumulated damage that justifies taking true overload seriously — and, by symmetry, justifies not trivializing the diagnosis in those who do not have it.
In established phenotypic overload, therapeutic phlebotomy is the treatment of choice: removing blood depletes iron effectively, mobilizing the stores and, when started before irreversible damage, preventing organ complications Powell et al., 2016. The indication, however, is precise: the guidelines reserve phlebotomy for cases with documented overload — elevated ferritin accompanied by evidence of iron deposits (through elevated saturation and, when indicated, hepatic magnetic resonance imaging or biopsy) — and not on the basis of isolated ferritin or an isolated genotype Bacon et al., 2011.
The order of factors matters clinically. First the overload phenotype is established; only then is it treated. A compatible genotype without biochemical or phenotypic expression does not characterize disease and is not, in itself, an indication for treatment Kowdley et al., 2019. On the other hand, a high ferritin whose origin is metabolic, alcoholic, or inflammatory calls for treating the cause — excess weight, steatosis, alcohol, the inflammatory process — and not for bleeding the patient in the expectation of correcting something that phlebotomy does not correct Zoller et al., 2022.
Anti-fad pitfalls: separating association from causation
The right question is not 'is ferritin high?', but 'is there real overload, and does phlebotomy correct the cause?'.
The first pitfall is to treat isolated elevated ferritin as iron overload. Without elevated transferrin saturation and/or confirmation of deposits by imaging or biopsy, high ferritin usually reflects inflammation, metabolic syndrome, steatosis, or alcohol — and in these cases there is no indication for phlebotomy Kell & Pretorius, 2014. The second is to presume hemochromatosis in a C282Y heterozygote or an H63D carrier: the isolated genotype, without biochemical expression, does not characterize the disease, given the incomplete penetrance Pilling et al., 2019.
The third pitfall goes in the opposite direction and is equally common: supplementing iron without proven deficiency. Supplementation is justified with documented deficiency — low ferritin and/or low saturation — and not on the basis of vague symptoms, nonspecific fatigue, or a 'borderline ferritin.' Supplementing without that basis is unjustified and may worsen stores in those who already tend to accumulate Camaschella, 2015.
The fourth, and conceptually the most important, is to confuse association with causation. High ferritin predicts hepatic and metabolic outcomes, but this reflects the underlying inflammation and hepatic fat — bleeding the patient does not correct the metabolic cause and may represent harm without benefit Kowdley et al., 2012. From this follows the fifth: do not promise that phlebotomy 'detoxifies iron' or improves energy and longevity in those without overload — the benefit of phlebotomy is proven in established phenotypic overload, not as a wellness intervention Powell et al., 2016.
The sixth pitfall closes the reasoning: do not start treatment based solely on a direct-to-consumer genetic test. Without confirming the phenotype — transferrin saturation, serial ferritin and, when indicated, hepatic iron magnetic resonance imaging — there is no diagnosis of overload, only a marker of population risk Bacon et al., 2011. Iron metabolism rewards interpretive discipline: two markers read together, the distinction between genotype and phenotype, and the humility to treat the cause of the high ferritin instead of treating the number.
Why this matters for your care
This article is part of the author's line of research on iron metabolism with interpretive rigor, a basis for reading laboratory tests in the Functional Self-Assessment and for the other texts in the Library. Educational content, in accordance with CFM guidelines: it does not constitute a diagnosis, prescription, or treatment recommendation, and does not replace individual medical evaluation. Ferritin, transferrin saturation, and HFE genetic tests must be interpreted by a qualified professional, within each person's complete clinical context. No promise of outcome, cure, or benefit from supplementation or phlebotomy is made outside the indications established in the indexed literature cited.
References
- Ganz T, Nemeth E. Hepcidin and iron regulation, 10 years later. Blood. 2011. doi:10.1182/blood-2011-01-258467
- Camaschella C. Iron-deficiency anemia. New England Journal of Medicine. 2015. doi:10.1056/NEJMra1401038
- Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 2014. doi:10.1039/c3mt00347g
- Zoller H, Schaefer B, Vanclooster A, Griffiths B, Bardou-Jacquet E, Corradini E, Porto G, Ryan J, Cornberg M (EASL). EASL Clinical Practice Guidelines on haemochromatosis. Journal of Hepatology. 2022. doi:10.1016/j.jhep.2022.03.033
- Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, Nelson JE. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012. doi:10.1002/hep.24706
- Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, et al. (HEIRS Study). Hemochromatosis and iron-overload screening in a racially diverse population. New England Journal of Medicine. 2005. doi:10.1056/NEJMoa041534
- Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS (AASLD). Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011. doi:10.1002/hep.24330
- Kowdley KV, Brown KE, Ahn J, Sundaram V (ACG). ACG Clinical Guideline: Hereditary Hemochromatosis. American Journal of Gastroenterology. 2019. doi:10.14309/ajg.0000000000000315
- Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. The Lancet. 2016. doi:10.1016/S0140-6736(15)01315-X
- Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. New England Journal of Medicine. 2008. doi:10.1056/NEJMoa073286
- Pilling LC, Tamosauskaite J, Jones G, Wood AR, Jones L, Kuo CL, Kuchel GA, Ferrucci L, Melzer D. Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank. BMJ. 2019. doi:10.1136/bmj.k5222
Educational and scientific content. It does not constitute diagnosis, prescription or individual clinical guidance, and does not replace a medical consultation. Management decisions must be individualized by a physician.